The Effect in Wedge Resection and IVb/V Resection of the Liver for Gallbladder Cancer

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age19-80
SponsorSaint Vincent's Hospital, Korea

About this trial

The extent of hepatic resection for gallbladder cancer can be done from a wedge resection to 4b/5 bisegmentectomy. This study aims to compare the recurrence rates and survival rates between wedge resection group and bisegmentectomy group. Patients with T2 or T3 gallbladder cancer on preoperative CT exam or patients who were pathologically diagnosed as T2 or T3 gallbladder cancer after initial simple cholecystectomy were enrolled. All patients are randomly assigned to wedge resection or bisegmentectomy group. Number of patients in each group is 44. Primary endpoint is recurrence-free-survival rates and overall survival rates.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with T2 or T3 gallbladder cancer on preoperative CT exam

Patients who are pathologically diagnosed as T2 or T3 gallbladder cancer after initial simple cholecystectomy

Disqualifiers

Peritoneal seeding or distant metastasis

Impossible to resect the cancer radically

Pathologically diagnosed to other malignancy such as adenosquamous carcinoma, sarcoma, etc.

R1 or R2 resection were pathologically diagnosed.

Trial design

Design model

Parallel

Treatments tested in this trial

  • wedge resection

    Procedure/Surgery

    The extent of hepatic resection is wedge resection of liver including gallbladder fossa

  • bisegmentectomy

    Procedure/Surgery

    The extent of hepatic resection is 4b/5 bisegmentectomy of liver

Treatment groups

88 Participants
are divided into 2 treatment groups
Group A: wedge resectionActive comparator 1 intervention
Group B: bisegmentectomyActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Survival rates

3year 5 year

Time frame
1 year

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.